Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects
Stopped early · Phase 1 · Has a placebo group
Conditions studied: Healthy
In brief
To evaluate whether PF-02545920 reduces the effects of ketamine on brain activation during causal learning as measured by fMRI compared to placebo in healthy human subjects, and to evaluate whether behavioral measures of abnormal causal learning under ketamine are reduced by treatment with PF 02545920.
Key facts
- Study ID
- NCT01244880
- Run by
- Pfizer
- People needed
- 4
- Starts
- 2011-04-01
- Expected to finish
- 2012-08-01
- Last updated by the study team
- 2014-03-21
Who can join
Age: 21 and older, up to 45. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Healthy male and/or female subjects between the ages of 21 and 45 years, inclusive. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs). (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests).
- Right handed as determined by handedness questionnaire.
- Able to read and write English as a primary language.
You may not qualify if…
- Female subjects who are pregnant or breastfeeding.
- Any evidence of significant psychosis-like symptoms.
- Known sensitivity to ketamine.
Where it is running
- Pfizer Investigational Site — New Haven, Connecticut, United States
- Pfizer Investigational Site — New Haven, Connecticut, United States
- Pfizer Investigational Site — New Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.